Research programme: granulocyte-macrophage colony-stimulating factor - Bolder BioTechnology

Drug Profile

Research programme: granulocyte-macrophage colony-stimulating factor - Bolder BioTechnology

Alternative Names: BBT-007; GM-CSF - Bolder BioTechnology; PEG-GM-CSF - Bolder BioTechnology; PEG-granulocyte-macrophage colony stimulating factor - Bolder BioTechnology

Latest Information Update: 09 Nov 2010

Price : $50

At a glance

  • Originator Bolder BioTechnology
  • Class Granulocyte-macrophage colony-stimulating factors; Polyethylene glycols
  • Mechanism of Action Immunomodulators; Neutrophil stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Neutropenia; Radiation injuries

Most Recent Events

  • 09 Nov 2010 Preclinical development in Neutropenia is ongoing in USA
  • 03 Nov 2010 Bolder BioTechnology receives Qualifying Therapeutic Discovery Project grant from the US Department of Health and Human Services for BBT 007 development in Radiation injuries and Neutropenia
  • 17 Sep 2009 Bolder BioTechnology receives SBIR grant from National Institute of Allergy and Infectious Diseases for long acting GM-CSF development in Acute radiation syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top